Sofinnova Investments

Sofinnova Investments. It is a venture capital firm based in London specializing in the life sciences sector, with a particular focus on early-stage and growth-stage companies across Europe and North America. Founded in 2000, the firm operates as an independent partnership, leveraging deep scientific expertise to invest in innovative biotechnology, medical device, and diagnostic companies. It is part of the broader Sofinnova Partners network, one of Europe's longest-standing life sciences investment platforms, but maintains its own dedicated fund and investment team.

History

The firm was established in 2000 by Anne Glover and Michele Ollier, both former partners at the Paris-based Sofinnova Partners. Its creation was driven by a strategy to build a dedicated, London-centric fund focused on the burgeoning life sciences opportunity within the United Kingdom and across Europe. The launch of its first fund, Sofinnova Capital I, marked a significant commitment to the sector. Over the subsequent decades, it has raised multiple successive funds, including the Sofinnova Capital III fund in 2019, consistently expanding its capital under management and its geographic reach to include compelling opportunities in North America. Key milestones in its history include early investments in companies like EUSA Pharma and UltraSight, which demonstrated its model of identifying and nurturing promising science.

Investment strategy

The investment strategy is rigorously focused on the life sciences sector, targeting companies that develop transformative therapies, technologies, and tools. It primarily engages in Series A and Series B financing rounds, providing crucial capital for clinical development and commercial expansion. The firm's approach is deeply hands-on, with partners taking active roles on boards and working closely with management teams on strategy, clinical trial design, and business development. It seeks investments in areas with high unmet medical need, such as oncology, rare diseases, central nervous system disorders, and innovative medical devices. This strategy is supported by a team with extensive operational experience in companies like GlaxoSmithKline and Genentech.

Portfolio companies

The firm's portfolio comprises numerous innovative companies that have achieved significant clinical and commercial milestones. Notable historical exits include EUSA Pharma, a specialty pharmaceutical company focused on oncology and rare diseases, which was acquired by Jazz Pharmaceuticals in 2012. Another success was UltraSight, a developer of ultrasound guidance technology, acquired by Teleflex. Current portfolio highlights feature companies like Mestag Therapeutics, an immuno-oncology biotech, and AviadoBio, which is developing gene therapies for neurodegenerative diseases such as frontotemporal dementia. Other active investments include Nuvectis Pharma, Pheon Therapeutics, and Pyrrosia Pharmaceuticals, each advancing novel therapeutic platforms.

Leadership and team

The firm is led by its co-founders, Anne Glover, who also serves as the Chief Executive Officer of Amadeus Capital Partners, and Michele Ollier, a seasoned investor with a background at Roche and GlaxoWellcome. The senior investment team includes partners such as James K. M. Brown and Nicolas de Cremoux, who bring decades of combined experience from leading roles in the biopharmaceutical industry and finance. The team's collective expertise spans drug discovery, clinical development, business development, and corporate finance, having held positions at organizations like Pfizer, Novartis, and Morgan Stanley. This operational depth is a cornerstone of the firm's ability to guide portfolio companies.

Impact and recognition

Through its investments, the firm has played a substantive role in advancing novel treatments to market, contributing to the growth of the European life sciences ecosystem. Its portfolio companies have progressed numerous compounds through clinical trials, addressing serious conditions and forging partnerships with major pharmaceutical companies. The firm and its leaders are regularly recognized within the industry; for instance, its partners are frequently featured on lists such as the Forbes Midas List of top venture capitalists. Its consistent fundraising success and the performance of its funds have established it as a respected and influential investor in the global biotechnology and healthcare investment landscape.

Category:Venture capital firms of the United Kingdom Category:Biotechnology companies Category:Companies based in London Category:Financial services companies established in 2000